GNAQ and Hepatic fibrosis: These results suggest that pharmacological inhibition of GPR65 could protect against hepatic fibrosis, thus providing new cues for harnessing hepatic fibrosis by developing innovative therapeutic approaches based on the GPR65-Gαq-Ca2+-JNK/NF-κB pathways (Fig. 8).